Phase 3, Single-administration, Open-label Trial to Assess the Efficacy, Safety, PK, and PD of Dasiglucagon When Administered as a Rescue Therapy for Severe Hypoglycemia in Pediatric Patients Below 6 Years of Age With Type 1 Diabetes (T1D)
Latest Information Update: 03 Sep 2024
Price :
$35 *
At a glance
- Drugs Dasiglucagon (Primary)
- Indications Hypoglycaemia
- Focus Registrational; Therapeutic Use
- Sponsors Zealand Pharma
- 29 Aug 2024 Planned primary completion date changed from 25 Mar 2024 to 25 Sep 2024.
- 28 Aug 2023 Planned End Date changed from 1 Jul 2023 to 25 Sep 2024.
- 28 Aug 2023 Planned primary completion date changed from 1 Jun 2023 to 25 Mar 2024.